Press release
SPL Medical announces collaboration with NanoEcho for application of Ferrotran® (Ferumoxtran) for Ultrasound detection of Lymph node metastases.
In NanoEcho's method for diagnostics of rectal cancer lymph node metastases, modern ultrasound technology is used together with iron-oxide nanoparticles. For the clinical effectiveness of the system, the choice of the appropriate nanoparticle is essential.
Ferrotran®, the lymphotropic nanoparticle of SPL medical, is in advanced phase III for the detection of lymph node metastases for prostate cancer patients with Magnetic Resonance Imaging (MRI).
The Ferrotran® particle has been developed as a platform technology for various applications for the broad base of installed MRI scanners worldwide.
With this collaboration with NanoEcho the Ferrotran® platform technology will be extended also to modern ultrasound technologies.
- "The extension of the scope of applicability of Ferrotran® to ultrasound technology demonstrates the wide power of our platform technology beyond the broad field of nano-MRI", says Dr. Jürgen Feuerstein CEO for SPL Medical.
- "We are very pleased to have established this collaboration with SPL medical. This is an important step in our journey. Based on our initial evaluation, the particle provided by SPL medical looks very promising for our application. Their expertise in the development and commercialization of nanoparticles is impressive and will be very beneficial for us at NanoEcho", says Dr. Linda Persson CEO for NanoEcho.
SPL medical BV, Toernooiveld 100 · 6525 EC Nijmegen, The Netherlands
Dr. Juergen Feuerstein (CEO): +49 171 173 5476
About SPL Medical:
SPL medical is a spin-off of the Radboud university medical center and is funded additionally by Oost NL, a Dutch regional venture capital company, and b.e. imaging GmbH, a German company specialized in the development and commercialization of contrast agents.
About Ferrotran®:
Ferrotran® belongs to the group of USPIO's (Ultrasmall Superparamagnetic Particles of Iron Oxide). Ferrotran® can be applied in MRI as a safe bloodpool agent for angiography and for functional diagnostics in detection of even the smallest lymph node metastases in prostate cancer patients and is currently under investigation for use in various other cancers.
Ferrotran® is safe, as it is based on iron and therefore metabolized naturally in the body.
Ferrotran® is in advanced phase III in various prestigious European University Hospitals. Ferrotran® has been applied successfully in over 700 patients in the Netherlands and Switzerland in special approval permissions.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release SPL Medical announces collaboration with NanoEcho for application of Ferrotran® (Ferumoxtran) for Ultrasound detection of Lymph node metastases. here
News-ID: 2754371 • Views: …
More Releases for Ferrotran®
Punch!® Software Releases Punch!CAD™ SharkCAD® & ViaCAD® 15
NOVATO, Calif., December 10, 2024 - Punch!® Software, a leading software developer of Home Design and CAD titles for over 25 years, today announced the release of new Windows and Mac versions of the SharkCAD® 15 and ViaCAD® 15 family of products.
This latest release encompasses a range of variants for the Windows and Macintosh platform: SharkCAD® Pro, SharkCAD®, ViaCAD® Pro, ViaCAD® 2D/3D, and ViaCAD® 2D.
Punch!CAD™ products continue to provide innovative…
SPL Medical has entered into an Agreement with NanoEcho for supply and applicati …
Nijmegen, The Netherlands, 27.02.2024 - The business agreement, signed today by SPL Medical and NanoEcho, is a comprehensive contract. The agreement grants NanoEcho exclusivity regarding the supply of ferumoxtran (iron oxide-based nanoparticles) for use in magnetomotive ultrasound.
For the clinical effectiveness of the NanoEcho system, the choice of nanoparticles is of crucial im-portance. Ferumoxtran is chosen based on its unique ability to spread in the lymphatic system and differentiate between diseased…
SPL Medical announces achievement of next major clinical development milestone f …
Nijmegen, The Netherlands, 02.08.2023 - SPL medical has its proprietary iron-based nano-particle Ferrotran® (Ferumoxtran) product and platform in clinical Phase III. The pivotal trial named PROSTAPROGRESS has now reached the next major milestone by inclusion of over 75% of the patients into this trial.
Major academic centers in The Netherlands, Belgium, Germany and Switzerland are contributing constantly.
With the PROSTAPROGRESS trial, SPL will verify the superior efficacy and state-of-the-art safety of Ferrotran®,…
SPL Medical announces achievement of major Phase III clini-cal development miles …
Nijmegen, The Netherlands, 14.12.2022 - SPL medical has its proprietary iron-based nano-particle Ferrotran® (Ferumoxtran) product and platform in clinical Phase III. The pivotal trial named PROSTAPROGRESS has now reached a major milestone by inclusion of more than 50 % of the planned patient group into this trial.
Major academic centres in The Netherlands, Belgium, Germany and Switzerland are contributing constantly.
With the PROSTAPROGRESS trial, SPL will verify the superior efficacy and state-of-the-art…
Novel algorithm for nano-MRI with Ferrotran® (Ferumoxtran) for the detection of …
SPL Medical announced today the publication and online availability of the full paper in Investigative Radiology about the use of Ferrotran® for the detection of even very small lymph nodes in patients with head & neck cancer. A new reading algorithm has been developed which is applicable to routine MRI instruments available in a big installed base in the market.
Conclusions by the authors
Radiological analysis revealed that metastatic lymph nodes showed…
Sunera Technologies, Inc Joins SAP® PartnerEdge® Delivering SAP® S/4HANA
Sunera Technologies, Inc Joins SAP® PartnerEdge® Delivering SAP® S/4HANA and Intelligent Enterprise to Manufacturing, Consumer Products, Higher education, and research, Industrial machinery and components, Life sciences and Automotive Industries
Chicago, IL, June 10, 2020 – Sunera Technologies, Inc announced that it had joined the SAP® PartnerEdge® program as a Re-sell & Services partner, through which it will resell SAP solutions to midsize organizations in North America. Through this engagement, SuneraTech…
